SUPONA AEROSOL

Indications

• Insecticide
• Acaricide

Mechanism of action

Chlorfenvinphos acts as an acetylcholinesterase inhibitor. By binding to the active site of the acetylcholinesterase enzyme, it prevents the breakdown of acetylcholine in the synaptic cleft. This leads to an accumulation of acetylcholine, resulting in continuous stimulation of the postsynaptic receptors, which disrupts normal neuronal signaling and causes paralysis in insects.

Pharmacodynamics

The pharmacodynamics of chlorfenvinphos involve its action as a neurotoxin. Its inhibition of acetylcholinesterase results in increased levels of acetylcholine, causing prolonged stimulation of cholinergic receptors. This can lead to symptoms such as muscle twitching, salivation, lacrimation, urination, diarrhea, gastrointestinal distress, and central nervous system effects, including seizures.

Pharmacokinetics

Chlorfenvinphos is absorbed through the skin, respiratory tract, and gastrointestinal tract. Once absorbed, it is distributed throughout body tissues. The compound is metabolized in the liver and excreted primarily through urine. The half-life and specific metabolic pathways can vary based on individual factors and exposure levels.

Contra-indications

• Hypersensitivity to chlorfenvinphos or any of its components
• History of seizures or epilepsy
• Severe liver or kidney impairment

Adverse effects

• Nausea
• Vomiting
• Diarrhea
• Abdominal pain
• Headache
• Dizziness
• Tremors
• Muscle twitching
• Respiratory distress

Interactions

• Cholinergic drugs may enhance the effects of chlorfenvinphos
• Anticholinergic drugs may counteract the effects of chlorfenvinphos

Precautions

• Use with caution in patients with asthma or other respiratory conditions
• Avoid use in patients with a history of cardiac disease
• Monitor for signs of cholinergic toxicity

Pregnancy

Chlorfenvinphos should be avoided during pregnancy due to potential risks to the fetus.

Breast-feeding

It is not recommended to breastfeed while using chlorfenvinphos due to potential harmful effects on the infant.

Storage

Store in a cool, dry place away from direct sunlight. Keep out of reach of children.

Formulations

• Liquid formulations for agricultural use
• Emulsifiable concentrates

Indications

• Insecticide
• Cognitive deficits in Alzheimer's disease

Dosage

Children: Refer to BNF for Children for specific dosing guidelines.

Adults: Refer to BNF for specific dosing guidelines.

Mechanism of action

Dichlorvos inhibits acetylcholinesterase, disrupting the breakdown of acetylcholine and resulting in prolonged neurotransmission at cholinergic synapses. It also inhibits acylpeptide hydrolase at lower doses, enhancing synaptic efficacy without affecting acetylcholinesterase. This dual action may contribute to its effects on cognitive function.

Pharmacodynamics

As a cholinesterase inhibitor, dichlorvos leads to increased levels of acetylcholine, enhancing cholinergic transmission. Its ability to inhibit acylpeptide hydrolase may contribute to improved synaptic plasticity, which is crucial for learning and memory. These mechanisms underline its potential therapeutic uses beyond its insecticidal properties.

Pharmacokinetics

Dichlorvos is absorbed through various routes, including oral and dermal. It undergoes rapid metabolism, primarily in the liver, and is excreted in urine. The pharmacokinetics can vary based on the route of exposure and individual factors such as age and health status.

Pregnancy

Dichlorvos is not recommended for use during pregnancy due to potential risks to the developing fetus.

Breast-feeding

It is not known whether dichlorvos is excreted in human milk. Caution should be exercised when administered to breastfeeding women.

Storage

Store in a cool, dry place, away from direct sunlight and moisture. Keep out of reach of children.

Indications

• Loss of appetite
• Dyspepsia
• Gastrointestinal disorders
• Digestive aid
• Bloating

Dosage

Children: Refer to established herbal guidelines, as specific dosing may vary based on preparation and indication.

Adults: Refer to established herbal guidelines, as specific dosing may vary based on preparation and indication.

Mechanism of action

The primary mechanism of action of gentian is attributed to its bitter compounds, which stimulate the taste receptors in the mouth and gastrointestinal tract. This stimulation increases the secretion of digestive juices, including saliva, gastric acid, and bile, thereby enhancing digestion and appetite. The presence of secoiridoids may also exert anti-inflammatory and antioxidant effects, contributing to its overall benefits.

Pharmacodynamics

Gentian exhibits pharmacodynamic effects primarily through its bitter principles that promote digestive processes. These compounds increase gastrointestinal motility and enhance nutrient absorption by stimulating the secretion of digestive enzymes. Gentian's potential effects on appetite regulation may also involve central nervous system pathways, although this mechanism is less well understood.

Pharmacokinetics

The pharmacokinetics of gentian are not extensively characterized due to its herbal nature. However, it is generally assumed that the active compounds are absorbed in the gastrointestinal tract after oral administration. The metabolism and excretion pathways remain largely undefined, given the complexity of the herbal preparation and the variability in individual responses.

Pregnancy

The safety of gentian during pregnancy has not been established. Use should be avoided unless deemed necessary by a healthcare professional.

Breast-feeding

Limited information is available on the excretion of gentian in breast milk. Caution is advised when administering to breastfeeding mothers.

Storage

Store in a cool, dry place away from direct sunlight. Keep out of reach of children.

Dosage

Children: Refer to specific product information for details on use as a coloring agent in formulations.

Adults: Refer to specific product information for details on use as a coloring agent in formulations.

Mechanism of action

The mechanism of action for violet dyes generally involves their ability to absorb specific wavelengths of light, which contributes to their coloring properties. In the context of pharmacology, they do not possess therapeutic effects but rather serve a functional role in drug formulation.

Pharmacodynamics

As a coloring agent, violet dyes do not exhibit pharmacodynamic properties associated with therapeutic agents. They do not interact with biological targets in the manner that active pharmaceutical ingredients do, and their primary role is to provide color rather than therapeutic efficacy.

Pharmacokinetics

Violet dyes, being non-active agents, do not undergo typical pharmacokinetic processes such as absorption, distribution, metabolism, and excretion in the same way that active drugs do. Their presence in formulations is primarily for aesthetic purposes, and they are typically excreted unchanged.

Pregnancy

Safety not established; consult healthcare provider.

Breast-feeding

Safety not established; consult healthcare provider.

Storage

Store in a cool, dry place, away from light.

Mechanism of action

Like other organophosphate agents, dichlorvos inhibits acetylcholinesterase interfering with neuromuscular transmission in susceptible parasites. Dichlorvos is the active molecule of the pro-drug metrifonate used to revert the cognitive deficits associated with Alzheimer's disease. A few years ago it was reported that dichlorvos inhibits the enzyme acylpeptide hydrolase at lower doses than those necessary to inhibit acetylcholinesterase to the same extent. Therefore, the aim of our investigation was to test the hypothesis that dichlorvos can enhance synaptic efficacy through a mechanism that involves acylpeptide hydrolase instead of acetylcholinesterase inhibition. We used long-term potentiation induced in rat hippocampal slices as a model of synaptic plasticity. Our results indicate that short-term exposures (20 min) to 50 uM dichlorvos enhance long-term potentiation in about 200% compared to the control condition. This effect is correlated with approximately 60% inhibition of acylpeptide hydrolase activity, whereas acetylcholinesterase activity remains unaffected. Paired-pulse facilitation and inhibition experiments indicate that dichlorvos does not have any presynaptic effect in the CA3-->CA1 pathway nor affect gabaergic interneurons. Interestingly, the application of 100 nM methyllicaconitine, an alpha(7) nicotinic receptor antagonist, blocked the enhancing effect of dichlorvos on long-term potentiation. These results indicate that under the exposure conditions described above, dichlorvos enhances long-term potentiation through a postsynaptic mechanism that involves (a) the inhibition of the enzyme acylpeptide hydrolase and (b) the modulation of alpha(7) nicotinic receptors. Exposure to dichlorvos (DDVP), an organophosphorus pesticide, is known to result in neurotoxicity as well as other metabolic perturbations. However, the molecular causes of DDVP toxicity are poorly understood, especially in cells other than neurons and muscle cells. To obtain a better understanding of the process of non-neuronal DDVP toxicity, we exposed zebrafish to different concentrations of DDVP, and investigated the resulting changes in liver histology and gene transcription. Functional enrichment analysis of genes affected by DDVP exposure identified a number of processes involved in energy utilization and stress response in the liver. The abundance of transcripts for proteins involved in glucose metabolism was profoundly affected, suggesting that carbon flux might be diverted toward the pentose phosphate pathway to compensate for an elevated demand for energy and reducing equivalents for detoxification. Strikingly, many transcripts for molecules involved in beta-oxidation and fatty acid synthesis were down-regulated. We found increases in message levels for molecules involved in reactive oxygen species responses as well as ubiquitination, proteasomal degradation, and autophagy. To ensure that the effects of DDVP on energy metabolism were not simply a consequence of poor feeding because of neuromuscular impairment, we fasted fish for 29 or 50 hr and analyzed liver gene expression in them. The patterns of gene expression for energy metabolism in fasted and DDVP-exposed fish were markedly different. We observed coordinated changes in the expression of a large number of genes involved in energy metabolism and responses to oxidative stress. These results argue that an appreciable part of the effect of DDVP is on energy metabolism and is regulated at the message level. Although we observed some evidence of neuromuscular impairment in exposed fish that may have resulted in reduced feeding, the alterations in gene expression in exposed fish cannot readily be explained by nutrient deprivation. The main target of neurotoxins is neurons because they comprise the main part of neural function, but glial cells may be indirect targets because they support the function of neurons. Among the glial cells, astrocytes in particular act as "nurse cells", regulating